1,800
Participants
Start Date
July 8, 2020
Primary Completion Date
July 8, 2024
Study Completion Date
July 8, 2025
Nivolumab
A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).
Pembrolizumab
A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.
Ipilimumab
A human immunoglobulin G1 (IgG1) monoclonal antibody raised against cytotoxic T lymphocyte antigen-4 (CTLA-4).
Durvalumab
A human immunoglobulin G1-kappa (IgG1-kappa) monoclonal antibody that binds to programmed death ligand 1 (PD-L1).
Tremelimumab
A fully human monoclonal antibody raised to target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
Atezolizumab
A humanised IgG1 monoclonal antibody raised to target programmed death-ligand 1 (PD-L1).
Bevacizumab
A humanised IgG1 monoclonal antibody raised to target vascular endothelial growth factor (VEGF).
RECRUITING
Royal United Hospitals Bath NHS Foundation Trust, Bath
RECRUITING
University Hospitals Dorest NHS Foundation Trust, Bournemouth
RECRUITING
University Hospitals Bristol NHS Foundation Trust, Bristol
RECRUITING
Cambridge University Hospitals NHS Foundation Trust, Cambridge
RECRUITING
Velindre University NHS Trust, Cardiff
RECRUITING
Western General Hospital, Edinburgh
RECRUITING
The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, Kings Lynn
RECRUITING
University Hospitals of Leicester NHS Foundation Trust, Leicester
RECRUITING
Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich
RECRUITING
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield
RECRUITING
University Hospital Southampton NHS Foundation Trust, Southampton
RECRUITING
Somerset NHS Foundation Trust, Taunton
RECRUITING
Royal Cornwall Hospitals NHS Trust, Truro
Collaborators (1)
Microbiotica Ltd
INDUSTRY
CCTU- Cancer Theme
OTHER